| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 16.431 | 131.149 | 123.004 | 114.055 | 139.749 | 151.193 | 178.457 | 233.459 | 264.841 | 298.479 |
| Total Income - EUR | 16.431 | 131.149 | 123.004 | 114.055 | 139.749 | 151.193 | 178.457 | 233.459 | 264.841 | 307.246 |
| Total Expenses - EUR | 1 | 2.917 | 3.380 | 3.562 | 7.722 | 11.036 | 11.137 | 12.027 | 12.518 | 14.649 |
| Gross Profit/Loss - EUR | 16.430 | 128.233 | 119.624 | 110.493 | 132.027 | 140.157 | 167.320 | 221.432 | 252.323 | 292.597 |
| Net Profit/Loss - EUR | 15.937 | 117.388 | 115.740 | 107.071 | 129.258 | 138.758 | 165.661 | 219.542 | 249.807 | 246.718 |
| Employees | 0 | 1 | 1 | 1 | 1 | 2 | 2 | 1 | 2 | 2 |
Check the financial reports for the company - Novagyn Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 153 | 0 | 0 | 6.861 | 4.973 | 3.157 | 1.411 | 101 | 101 | 101 |
| Current Assets | 16.475 | 121.932 | 117.398 | 101.459 | 131.033 | 142.272 | 170.818 | 284.845 | 258.659 | 553.430 |
| Inventories | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Receivables | 7.721 | 7.519 | 7.263 | 8.030 | 10.812 | 12.796 | 14.095 | 237.240 | 26.079 | 269.261 |
| Cash | 8.753 | 114.413 | 110.136 | 93.429 | 120.221 | 129.476 | 156.723 | 47.605 | 232.580 | 284.170 |
| Shareholders Funds | 15.982 | 117.441 | 115.792 | 107.123 | 129.308 | 138.807 | 165.710 | 220.604 | 250.866 | 246.766 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 646 | 4.490 | 1.606 | 1.197 | 6.698 | 6.621 | 6.519 | 64.342 | 7.893 | 306.765 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Novagyn Srl